Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ -86.17M | $ 0.00 | $ 0.00 | $ -41.29M |
| Operating Income | $ -188.00M | $ -140.44M | $ -110.87M | $ -96.61M | $ -57.92M |
| EBITDA | $ -173.33M | $ -134.28M | $ -94.37M | $ -80.75M | $ -57.39M |
| Net Income | $ -183.44M | $ -126.64M | $ -92.91M | $ -82.34M | $ -46.24M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 187.65M | $ 210.40M | $ 149.38M | $ 166.20M | $ 248.93M |
| Total Assets | $ 250.77M | $ 235.40M | $ 183.20M | $ 203.88M | $ 272.01M |
| Total Debt | $ 6.31M | $ 7.32M | $ 8.23M | $ 8.19M | $ 5.91M |
| Net Debt | $ -92.34M | $ -24.47M | $ -48.01M | $ -22.54M | $ -44.68M |
| Total Liabilities | $ 155.38M | $ 28.82M | $ 22.18M | $ 18.79M | $ 14.82M |
| Stockholders' Equity | $ 95.39M | $ 206.58M | $ 161.03M | $ 185.09M | $ 257.19M |
| Cash Flow | |||||
| Free Cash Flow | $ -153.34M | $ -89.67M | $ -76.46M | $ -79.06M | $ -30.25M |
| Operating Cash Flow | $ -152.91M | $ -89.23M | $ -75.26M | $ -78.13M | $ -30.17M |
| Investing Cash Flow | $ 91.02M | $ -84.72M | $ 41.41M | $ 57.86M | $ -147.65M |
| Financing Cash Flow | $ 159.73M | $ 150.71M | $ 58.12M | $ 1.58M | $ 212.12M |
KalVista Pharmaceuticals Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.